Publisher: Mirage

ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.

“Our data demonstrates that SB-216 effectively inhibits PDAC cell growth through inhibiting oncogenic microtubules and mitochondrial function.”

The gut microbiome — made up of trillions of microbes in the digestive tract — is vital for digestion and overall health.

Cancer researchers at the University of Tennessee Health Science Center have published three groundbreaking studies demonstrating how advanced artificial intelligence and population health analytics can identify and address barriers to quality cancer care.

Children born to mothers with obesity, gestational diabetes mellitus or a hypertensive disorder of pregnancy have higher systolic and diastolic blood pressure than children born to mothers without these risk factors, according to a new USC study.

Immunotherapy, using a patient’s own immune system to treat disease, has shown promise in some patients with cancer but has not worked in most.

The University of Tennessee-Oak Ridge Innovation Institute, or UT-ORII, has selected circular bioeconomy systems and radiopharmaceutical therapies as its two newest Convergent Research Initiatives (CRIs), areas of joint research for UT and Oak Ridge National Laboratory. Over the next five years, UT and Oak Ridge National Laboratory, or ORNL, will invest $40 million-$20 million per… Read More

Findings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obstruction (MBO) provide important evidence to help inform clinical decision-making in managing this frequent complication in patients with advanced cancer.